Provided by Tiger Trade Technology Pte. Ltd.

Regeneron Pharmaceuticals

823.82
+24.743.10%
Post-market: 823.940.1200+0.01%19:58 EDT
Volume:682.68K
Turnover:558.92M
Market Cap:84.82B
PE:20.37
High:824.63
Open:808.86
Low:804.32
Close:799.08
52wk High:847.00
52wk Low:541.00
Shares:102.95M
Float Shares:98.88M
Volume Ratio:1.05
T/O Rate:0.69%
Dividend:3.64
Dividend Rate:0.44%
EPS(TTM):40.43
EPS(LYR):41.48
ROE:14.04%
ROA:6.53%
PB:2.67
PE(LYR):19.86

Loading ...

Regeneron Pharmaceuticals Inc : HSBC Cuts Target Price to $800 from $990

THOMSON REUTERS
·
Jul 06

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 03

Movement Alert|Regeneron Pharmaceuticals Rises 3.1% in Regular Trading, Selected for FDA Production Pilot Plus Priority Review for Novel Drug

Market Focus
·
Jul 02

Analysts Conflicted on These Healthcare Names: Alumis Inc. (ALMS), Glaukos (GKOS) and Regeneron (REGN)

TIPRANKS
·
Jul 01

Regeneron Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Jul 01

US FDA - Amneal, Cellares, Eli Lilly, Fujifilm, Kriya, Kyowa Kirin, Regeneron Join FDA Precheck Pilot

THOMSON REUTERS
·
Jun 30

Market Chatter: Eli Lilly, Regeneron Among First Companies in FDA PreCheck Pilot Program

MT Newswires Live
·
Jun 30

Lilly, Regeneron Selected for US Program to Review New Manufacturing Plants Faster

Reuters
·
Jun 30

Eli Lilly, Regeneron among first selections for FDA PreCheck program, CNBC says

TIPRANKS
·
Jun 30

Eli Lilly, Regeneron Among First Companies Selected for FDA Initiative to Speed Review of New Manufacturing Facilities - CNBC

THOMSON REUTERS
·
Jun 30

Healthcare Stocks Have Become a Haven for Investors Ditching Tech

Dow Jones
·
Jun 27

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jun 27

How Investors May Respond To Regeneron Pharmaceuticals (REGN) Cemdisiran Priority Review for gMG Treatment

Simply Wall St.
·
Jun 27

Regeneron Updates Financial Calendar for Second-quarter Results Release and Conference Call

Reuters
·
Jun 26

Regeneron’s New First-in-Human Eczema Drug REGN20423: Early Trial Progress and Investor Takeaways

TIPRANKS
·
Jun 26

Kymera Rises on Accelerated Trial Timeline for Experimental Eczema Drug

Reuters
·
Jun 25

AbbVie is buying a biotech working on an experimental eczema drug for $10.9 billion

Dow Jones
·
Jun 22

Regeneron Gets FDA, EMA Review of Cemdisiran in Generalized Myasthenia Gravis

Dow Jones
·
Jun 22

Regeneron says FDA accepts cemdisiran gMG filing for priority review

Reuters
·
Jun 22

Regeneron Pharmaceuticals - FDA to Review Cemdisiran Nda Under Priority Review With Target Action Date November 2026

THOMSON REUTERS
·
Jun 22